Literature DB >> 20478741

Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.

W Vaughn McCall1, Jill N Blocker, Ralph D'Agostino, James Kimball, Niki Boggs, Barbara Lasater, Peter B Rosenquist.   

Abstract

OBJECTIVE: Insomnia has been linked to suicidal ideas and suicide death in cross-sectional and longitudinal population-based studies. A link between insomnia and suicide has not been previously examined in the setting of a clinical trial. Herein we describe the relationship between insomnia and suicidal thinking during the course of a clinical trial for depression with insomnia.
METHODS: Sixty patients aged 41.5±12.5 years (2/3 women) with major depressive episode and symptoms of insomnia received open-label fluoxetine for 9 weeks and also received blinded, randomized eszopiclone 3mg or placebo at bedtime after the first week of fluoxetine. Insomnia symptoms were assessed with the Insomnia Severity Index (ISI), and suicidal ideation was assessed with The Scale for Suicide Ideation (SSI). Depression symptoms were assessed with the depressed mood item and the anhedonia item from the Hamilton Rating Scale for Depression-24 (HRSD24), as well as a sum score for all non-sleep and non-suicide items from the HRSD (HRSD20). Measurements were taken at baseline and weeks 1, 2, 4, 6, and 8. SSI was examined by generalized linear mixed models for repeated measures as the outcome of interest for all 60 participants with ISI and various mood symptoms as independent variables, with adjustment for age, gender, treatment assignment, and baseline SSI.
RESULTS: Higher levels of insomnia corresponded to significantly greater intensity of suicidal thinking (p<0.01). The depressed mood item of the HRSD, and the sum of the HRSD20, both corresponded to greater suicidal thinking (p<0.001). The anhedonia item did not correspond with suicidal thinking. When both ISI and the depressed mood item, or ISI and the anhedonia item, were included together in the same model, the ISI remained an independent predictor of suicidal thinking.
CONCLUSIONS: The results support the concept that insomnia may be a useful indicator for suicidal ideation and now extend this idea into clinical trials. Insomnia remains an independent indicator of suicidal ideation, even taking into account the core symptoms of depression such as depressed mood and anhedonia. The complaint of insomnia during a depression clinical trial might indicate that more direct questioning about suicide is warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20478741      PMCID: PMC2936685          DOI: 10.1016/j.sleep.2010.04.004

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  56 in total

1.  Residual symptoms in depressed patients who respond acutely to fluoxetine.

Authors:  A A Nierenberg; B R Keefe; V C Leslie; J E Alpert; J A Pava; J J Worthington; J F Rosenbaum; M Fava
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

2.  Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression.

Authors:  P D Londborg; W T Smith; V Glaudin; J R Painter
Journal:  J Affect Disord       Date:  2000-12       Impact factor: 4.839

3.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.

Authors:  C H. Bastien; A Vallières; C M. Morin
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

4.  Subjective sleep quality and suicidality in patients with major depression.

Authors:  M Y Ağargün; H Kara; M Solmaz
Journal:  J Psychiatr Res       Date:  1997 May-Jun       Impact factor: 4.791

5.  Relief of expressed suicidal intent by ECT: a consortium for research in ECT study.

Authors:  Charles H Kellner; Max Fink; Rebecca Knapp; Georgios Petrides; Mustafa Husain; Teresa Rummans; Martina Mueller; Hilary Bernstein; Keith Rasmussen; Kevin O'connor; Glenn Smith; A John Rush; Melanie Biggs; Shawn McClintock; Samuel Bailine; Chitra Malur
Journal:  Am J Psychiatry       Date:  2005-05       Impact factor: 18.112

6.  Sleep and adolescent suicidal behavior.

Authors:  Xianchen Liu
Journal:  Sleep       Date:  2004-11-01       Impact factor: 5.849

7.  Suicidality and sleep disturbances.

Authors:  Rebecca A Bernert; Thomas E Joiner; Kelly C Cukrowicz; Norman B Schmidt; Barry Krakow
Journal:  Sleep       Date:  2005-09       Impact factor: 5.849

8.  Risk factors for late-life suicide: a prospective, community-based study.

Authors:  Carolyn L Turvey; Yeates Conwell; Michael P Jones; Caroline Phillips; Eleanor Simonsick; Jane L Pearson; Robert Wallace
Journal:  Am J Geriatr Psychiatry       Date:  2002 Jul-Aug       Impact factor: 4.105

9.  Sleep disturbance preceding completed suicide in adolescents.

Authors:  Tina R Goldstein; Jeffrey A Bridge; David A Brent
Journal:  J Consult Clin Psychol       Date:  2008-02

10.  Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

Authors:  Roy H Perlis; Shaun Purcell; Maurizio Fava; Jesen Fagerness; A John Rush; Madhukar H Trivedi; Jordan W Smoller
Journal:  Arch Gen Psychiatry       Date:  2007-06
View more
  71 in total

1.  Suicidal ideation and the subjective aspects of depression.

Authors:  John G Keilp; Michael F Grunebaum; Marianne Gorlyn; Simone LeBlanc; Ainsley K Burke; Hanga Galfalvy; Maria A Oquendo; J John Mann
Journal:  J Affect Disord       Date:  2012-03-09       Impact factor: 4.839

2.  Neurophysiological correlates of suicidal ideation in major depressive disorder: Hyperarousal during sleep.

Authors:  Michael R Dolsen; Philip Cheng; J Todd Arnedt; Leslie Swanson; Melynda D Casement; Hyang Sook Kim; Jennifer R Goldschmied; Robert F Hoffmann; Roseanne Armitage; Patricia J Deldin
Journal:  J Affect Disord       Date:  2017-01-26       Impact factor: 4.839

3.  Insomnia and suicidal ideation in nonaffective psychosis.

Authors:  Brian J Miller; Carmen B Parker; Mark H Rapaport; Peter F Buckley; William V McCall
Journal:  Sleep       Date:  2019-02-01       Impact factor: 5.849

4.  Efficacy of digital CBT for insomnia to reduce depression across demographic groups: a randomized trial.

Authors:  Philip Cheng; Annemarie I Luik; Cynthia Fellman-Couture; Edward Peterson; Christine L M Joseph; Gabriel Tallent; Kieulinh Michelle Tran; Brian K Ahmedani; Timothy Roehrs; Thomas Roth; Christopher L Drake
Journal:  Psychol Med       Date:  2018-05-24       Impact factor: 7.723

5.  Sleeping problems and suicide in 75,000 Norwegian adults: a 20 year follow-up of the HUNT I study.

Authors:  Johan Håkon Bjørngaard; Ottar Bjerkeset; Pål Romundstad; David Gunnell
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

Review 6.  Psychiatric disorders and sleep.

Authors:  Andrew D Krystal
Journal:  Neurol Clin       Date:  2012-11       Impact factor: 3.806

7.  Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.

Authors:  Sharon C Sung; Stephen R Wisniewski; James F Luther; Madhukar H Trivedi; A John Rush
Journal:  J Affect Disord       Date:  2014-11-22       Impact factor: 4.839

8.  Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity.

Authors:  Andrew D Krystal; W Vaughn McCall; Maurizio Fava; Hadine Joffe; Claudio N Soares; Holly Huang; Todd Grinell; Jacqueline Zummo; William Spalding; Randall Marshall
Journal:  Prim Care Companion CNS Disord       Date:  2012-07-05

Review 9.  Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.

Authors:  Faryal Mallick; Cheryl B McCullumsmith
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

10.  The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence.

Authors:  David J Allsop; Delwyn J Bartlett; Jennifer Johnston; David Helliwell; Adam Winstock; Iain S McGregor; Nicholas Lintzeris
Journal:  J Clin Sleep Med       Date:  2015-10-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.